A Phase 1 interventional study of balcinrenone/dapagliflozin in Healthy Volunteer, sponsored by AstraZeneca. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-15.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is intended to evaluate the PK, safety, and tolerability of balcinrenone/dapagliflozin given as a single dose capsule to healthy Chinese participants.
This is a Phase I, open-label, single-arm, single dose PK study in healthy Chinese participants to be conducted at a single study centre in mainland China. In this study, approximately 10 participants (both females and males) will be assigned to the IMP. Each participant will receive a single dose of a capsule with balcinrenone/dapagliflozin 40 mg/10 mg on Day 1 under fasted condition. The study will comprise of the following:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age
Participant aged 18 to 50 years.
Type of Participant and Disease Characteristics
Chinese participants who are healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests.
Weight
Exclusion Criteria:
Medical Conditions
History of severe allergy/ or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to balcinrenone or dapagliflozin.
Prior/Concomitant Therapy
Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), hormone replacement therapy, herbal remedies, megadose vitamins and minerals within 14 days or 5 half-lives (whichever is longer) before the start of IMP, unless, in the opinion of the investigator, the medication will not interfere with the study.
Prior/Concurrent another Clinical Study Experience
Has received product within 3 months (or 5 half-lives, whichever is longer) of administration of study intervention in this study.
Other Exclusions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To evaluate the PK of balcinrenone /dapagliflozin given as a single dose to healthy Chinese participants
Drug: balcinrenone/dapagliflozin
Drug pages: AZD9977 · Dapagliflozin
Each participant will receive a single dose of balcinrenone/dapagliflozin 40 mg/10 mg capsule on Day 1 under fasted condition. Each participant will be involved in the study for up to 35 days.
AUCinf of AUCinf of balcinrenone/dapagliflozin
To evaluate the PK of balcinrenone /dapagliflozin given as a single dose to healthy Chinese participants
Time frame: Day 1 to post dose 48 hours
AUClast of balcinrenone /dapagliflozin
To evaluate the PK of balcinrenone /dapagliflozin given as a single dose to healthy Chinese participants
Time frame: Day 1 to post dose 48 hours
Cmax of balcinrenone /dapagliflozin
To evaluate the PK of balcinrenone /dapagliflozin given as a single dose to healthy Chinese participants
Time frame: Day 1 to post dose 48 hours
C24h of balcinrenone /dapagliflozin
To evaluate the PK of balcinrenone /dapagliflozin given as a single dose to healthy Chinese participants
Time frame: Day 1 to post dose 48 hours
tmax of balcinrenone /dapagliflozin
To evaluate the PK of balcinrenone /dapagliflozin given as a single dose to healthy Chinese participants
Time frame: Day 1 to post dose 48 hours
t½λz of balcinrenone /dapagliflozin
To evaluate the PK of balcinrenone /dapagliflozin given as a single dose to healthy Chinese participants
Time frame: Day 1 to post dose 48 hours
λz of balcinrenone /dapagliflozin
To evaluate the PK of balcinrenone /dapagliflozin given as a single dose to healthy Chinese participants
Time frame: Day 1 to post dose 48 hours
CL/F of balcinrenone /dapagliflozin
To evaluate the PK of balcinrenone /dapagliflozin given as a single dose to healthy Chinese participants
Time frame: Day 1 to post dose 48 hours
MRTinf of balcinrenone /dapagliflozin
To evaluate the PK of balcinrenone /dapagliflozin given as a single dose to healthy Chinese participants
Time frame: Day 1 to post dose 48 hours
Vz/F of balcinrenone /dapagliflozin
To evaluate the PK of balcinrenone /dapagliflozin given as a single dose to healthy Chinese participants
Time frame: Day 1 to post dose 48 hours
Incidence of AEs and SAEs
To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants
Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)
Incidence of abnormal Supine blood pressure
To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants
Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)
Incidence of abnormal Supine Pulse
To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants
Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)
Height in centimeter
This is related to Body Mass Index, To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants
Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)
Weight in Kilograms
This is related to Body Mass Index, To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants
Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)
Incidence of abnormal clinical chemistry assessments:Glucose, HbA1c, Creatinine, , ALP, ALP, ALT, AST, total bilirubin, Potassium, Chloride, Bicarbonate, Calcium (total), magnesium, Phosphorous, Sodium, CK, eGFR, FSH, hCG
To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants
Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)
Incidence of abnormal urinalysis: Glucose, Haemoglobin, Protein/Albumin, hCG
To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants
Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)
Incidence of abnormal haematology assessments: Haematocrit, Hb, Platelet count, RBC, WBC
To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants
Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)
Incidence of abnormal of Electrocardiogram parameter: ECG mean heart rate
To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants
Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)
Incidence of abnormal of Electrocardiogram parameter: ECG Heart rhythm
To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants
Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)
Incidence of abnormal of Electrocardiogram parameter: ECG QRS duration, QT interval, QTc interval Fridericia
To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants
Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)
Incidence of abnormal physical examination: assessments of general appearance, respiratory, CV, abdomen, neurological systems, the skin, lymph nodes
To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants
Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)
Incidence of abnormal physical examination: assessment of the presence and extent of peripheral (ankle/leg) oedema
To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants
Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
No publications or documents are linked to this record.
Ran from Oct 2024 to primary completion in Oct 2024, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: AZD9977 · Dapagliflozin